

TDS/HY
JAN 14 2002 1642
TECH CENTER 1600/2900

PATENT

JAN 10 2002

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) M. Suthanthiran Examiner: Unassigned
Serial No.: 09/780,953 Group Art Unit: Unassigned
Confirmation No: 1712 Docket: 955-3P/CON
Filed: February 9, 2001 Dated: November 13, 2001
For: USE OF TGF- β
ANTAGONISTS TO
INHIBIT TUMOR CELL
FORMATION OR
PROGRESSION

Assistant Commissioner for Patents
Washington, DC 20231

*I hereby certify this correspondence is being deposited
with the United States Postal Service as first class mail,
postpaid in an envelope, addressed to:
Assistant Commissioner for Patents, Washington, D.C.*

20231 on November 13, 2001

Signed: Carla M. Bryan

INFORMATION DISCLOSURE STATEMENT

Sir:

In order to fulfill the requirements of candor and good faith set forth in 37 C.F.R. §1.56, Applicants submit herewith the following Information Disclosure Statement in accordance with the provisions of 37 C.F.R. §1.97 and §1.98.

UNITED STATES PATENTS

<u>PATENTEE</u>	<u>PATENT NO.</u>	<u>ISSUE DATE</u>
Logan et al.	5,958,411	September 28, 1999
Border	5,824,655	October 20, 1998
Grainger et al.	5,595,722	January 21, 1997
Ruoslahti et al.	5,583,103	December 10, 1996

<u>PATENTEE</u>	<u>PATENT NO.</u>	<u>ISSUE DATE</u>
Iwata et al.	5,262,319	November 16, 1993


NON-PATENT PUBLICATIONS (ARTICLES)

1. Hojo et al., "Cyclosporine Induces Cancer Progression by a Cell-autonomous Mechanism", Nature (1999), **397**(6719): 530-534.
2. Gary J. Nabel, "A Transformed View of Cyclosporine", Nature (1999), **397**: 471-472.
3. Carlos L. Arteaga et al. "Reversal of Tamoxifen Resistance of Human Breast Carcinomas *In Vivo* by Neutralizing Antibodies to Transforming Growth Factor- β ", Journal of the National Cancer Institute (1999), **91**(1): 46-53.
4. Wojtowicz-Praga et al. "Modulation of B16 Melanoma Growth and Metastasis by Anti-Transforming Growth Factor β Antibody and Interleukin-2", Journal of Immunotherapy (1996), **19**: 169-175.
5. Carlos L. Arteaga et al. "Anti-Transforming Growth Factor (TGF)- β Antibodies Inhibit Breast Cancer Cell Tumorigenicity and Increase Mouse Spleen Natural Killer Cell Activity", J. Clin. Invest. (1993), **92**: 2569-2576.
6. Magdalene Hoefer et al., "Anti-(transforming growth factor β) Antibodies with Predefined Specificity Inhibit Metastasis of Highly Tumorigenic Human Xenotransplants in nu/nu Mice", Cancer Immunol Immunother (1995), **41**: 302-308.

The above-referenced documents are listed on PTO Form 1449. We have enclosed the cited documents to facilitate reference to them. The Information Disclosure Statement is submitted before the first Office Action, therefore, it is believed that no fee is due. However, if a fee is due, the Commissioner is also hereby authorized to charge any fees associated with this communication to Deposit Account No. 08-2461. A duplicate copy of this paper is attached for that purpose.

Applicants are not aware of any other references to be identified at this time. If the Examiner has any questions or comments relating to the present application, he or she is respectfully invited to contact Applicants' attorney at the telephone number set forth below.

Respectfully submitted,



Algis Anilionis, Ph.D.
Registration No.: 36,995
Attorney for Applicant(s)

HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, New York 11791
(516) 822-3550
EIG/AA/jb/cb

144525_1.DOC